1Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy : National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA ,2000,283 : 1183-1188.
3Fett JD, Christie LG, Can'away RD, et al. Five-year pro-spective study of theincidence and prognosis of peripartum cardiomyopathy at a single insti- tution. Mayo Clinic Proceedings ,2005,80 : 1602-1606.
4Lfiker Kleiner D, Sliwa K, Drefler H, et al. Pefipartum Car-diomyopathy: Recent InsiSihs in its Pathophysiology. Trends Cardiovase Med Vol, 2008,18 : 173-179.
5Hilfiker KD, Sliwa K, Drefler H, et al. Peripartum Cardiomyopathy: Re- cent Insi Silts in its Pathophysiology. TCM ,2008,18 : 173-179.
6Hilfiker KD,Kaminski K. A Ca-thepsin D. Cleaved 16 kDa Form of Pm- lactin Mediates Postpa-rtum Cardiomyopathy. Ce11,2006,128:589-600.
8Sliwa K, Blauwet I, Tibazarwa K, et al. Evaluation of bromocr iptine in the treatment of acute severe peripartum cardiom yopathy a proof of concept pilot study. Circulation ,2010,121 : 1465-1473.
6Caiola K, Cheng JW. Use of erythropoietin in heart failure management. Ann. Pharmacother,2004 ,38 :2145-2149.
7van der Meer P, voors AA, Lipsic E, et al. Erythropoietin in. cardio, vas- cular, diseases. Eur Heart,2004,25 : 149-154.
8Silverberg DS, Wexler D,laina A. The importance of anemia and its cor- rection in the management of severe congestive heart failure. Eur J Heart fail ,2002,4:681-686.
9Kalra PR, Anagnostopoulos C, Bolger AP, et al. The regulation and meas- urement of plasma volume in heart failure. J Am Coil Cardiol, 2002,39: 1901-1908.
10Iverson PO. Wolback PR,Tonnessen J, et al. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol, 2002, 282 : 166-172.
